We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

58 hedge funds and large institutions have $54M invested in Kinnate Biopharma Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more call options, than puts

Call options by funds: $30K | Put options by funds: $3K

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

19% less funds holding

Funds holding: 72 → 58 (-14)

27% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 22

55% less capital invested

Capital invested by funds: $121M → $54M (-$67.4M)

67% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 21

Holders
58
Holders Change
-14
Holders Change %
-19.44%
% of All Funds
0.92%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
7
Increased
16
Reduced
22
Closed
21
Calls
$30K
Puts
$3K
Net Calls
+$27K
Net Calls Change
-$39K

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$1.01M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$830K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$735K
4
Renaissance Technologies
Renaissance Technologies
New York
+$404K
5
BCM
Bridgeway Capital Management
Texas
+$347K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.04M
2
BC
Boxer Capital
California
-$1.49M
3
HMC
Harvard Management Company
Massachusetts
-$1.4M
4
Millennium Management
Millennium Management
New York
-$829K
5
RSCM
Rock Springs Capital Management
Maryland
-$819K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management IV
California
$13.5M – – –
O
2
OrbiMed
New York
$11.2M – – –
FCMV
3
Foresite Capital Management V
California
$4.94M – – –
NI
4
Nextech Invest
Switzerland
$3.26M – – –
VVA
5
Vida Ventures Advisors
Massachusetts
$3.09M – – –
LCM
6
Lynx1 Capital Management
Puerto Rico
$2.8M -$124K -51,730 -3%
Viking Global Investors
7
Viking Global Investors
Connecticut
$2.55M – – –
Citadel Advisors
8
Citadel Advisors
Florida
$1.48M -$63.7K -26,543 -2%
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.39M – – –
NHAS
10
Novo Holdings A/S
Denmark
$1.14M – – –
BlackRock
11
BlackRock
New York
$1.04M +$44.1K +18,348 +3%
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$1.03M +$735K +305,884 +71%
Millennium Management
13
Millennium Management
New York
$780K -$829K -344,984 -38%
Renaissance Technologies
14
Renaissance Technologies
New York
$708K +$404K +168,156 +50%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$629K +$830K +345,572 +333%
Citigroup
16
Citigroup
New York
$589K +$1.01M +419,795 +53,139%
RSCM
17
Rock Springs Capital Management
Maryland
$568K -$819K -341,162 -46%
GCP
18
GSA Capital Partners
United Kingdom
$524K +$322K +133,948 +56%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$310K +$89K +37,071 +20%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$204K +$929 +387 +0.3%
BCM
21
Bridgeway Capital Management
Texas
$202K +$347K +144,300 New
Two Sigma Investments
22
Two Sigma Investments
New York
$192K +$57.6K +23,967 +21%
Deutsche Bank
23
Deutsche Bank
Germany
$161K – – –
Two Sigma Advisers
24
Two Sigma Advisers
New York
$150K +$215K +89,600 +515%
DCM
25
DAFNA Capital Management
California
$147K +$60K +25,000 +31%
1
2 3 4

KNTE Hedge Fund Activity: Q3 2023 in Review

58 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q3 2023, worth a combined $54M — down 55% from $121M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of KNTE and 7 opened new positions — a net loss of 14 holders — while 22 trimmed existing stakes and 16 added.

The largest buyer was Citigroup, adding an estimated $1.01M. The largest seller was Fidelity Investments, exiting entirely with an estimated $2.04M sold.

  • 58 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q3 2023, down from 72 in Q2 2023.
  • Funds reported $54M of Kinnate Biopharma Inc. Common Stock stock for Q3 2023, down 55% quarter-over-quarter.
  • 7 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q3 2023 and 21 closed out, a net change of -14 holders.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q3 2023 was Citigroup, an estimated $1.01M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q3 2023 was Fidelity Investments, an estimated $2.04M sold.

Based on aggregated 13F filings for Q3 2023.